Runben Biotechnology (SH:603193) Sou Hu Cai Jing·2025-07-30 09:29Core Viewpoint - Runben Biotechnology Co., Ltd. has shown significant revenue growth in its latest quarterly report, indicating a positive financial trajectory despite a recent decline in stock price [1]. Financial Performance - As of the first quarter of 2025, the company reported total revenue of 240 million yuan, representing a year-on-year increase of 44% [1]. - The net profit attributable to shareholders was 44.2 million yuan, up 24.6% year-on-year [1]. - The company's non-recurring net profit reached 38.6 million yuan, reflecting a growth of 22.85% compared to the previous year [1]. - Key financial ratios include a current ratio of 9.71, a quick ratio of 8.639, and a debt-to-asset ratio of 7.69% [1]. Stock Performance - As of July 30, 2025, the stock price closed at 33.34 yuan, down 3.22% [1]. - The trading volume was 133,200 hands, with a total transaction amount of 448 million yuan [1]. - The net inflow of main funds was 14.7 million yuan, accounting for 3.29% of the transaction amount [1]. Company Overview - Runben Biotechnology was established in 2013 and is based in Guangzhou, primarily engaged in the manufacturing of chemical raw materials and products [1]. - The company has a registered capital of 4.0459 billion yuan, with the same amount paid in [1]. - The legal representative of the company is Zhao Guiqin [1]. Investment and Intellectual Property - The company has made investments in 8 enterprises and participated in 13 bidding projects [2]. - It holds 106 trademark registrations and 109 patents, along with 64 administrative licenses [2].